CME in Minutes: Education in Cardiology & Pulmonology

Please visit answersincme.com/860/04572-replay2 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Cedric James Franklin Rutland, MD, FCCP; Stephanie Christenson, MD, MAS; and Surya P. Bhatt, MD, MSPH. In this activity, experts in chronic obstructive pulmonary disease (COPD) discuss the role of eosinophil testing, biologic therapies, and strategies for individualized, guideline-based treatment. Upon completion of this activity, participants should be better able to: Recognize the role of eosinophils and eosinophilic testing in COPD; Select biologic therapies for appropriate patients with eosinophilic COPD, based on the latest evidence and guidance; and Collaborate with an interdisciplinary team to integrate the latest guideline recommendations into individualized treatment plans tailored to patient and disease characteristics. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/860/04572-replay1 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Cedric James Franklin Rutland, MD, FCCP; Stephanie Christenson, MD, MAS; and David Mannino, MD, FCCP, FERS. In this activity, experts in chronic obstructive pulmonary disease (COPD) discuss the role of eosinophil testing, biologic therapies, and strategies for individualized, guideline-based treatment. Upon completion of this activity, participants should be better able to: Recognize the role of eosinophils and eosinophilic testing in COPD; Select biologic therapies for appropriate patients with eosinophilic COPD, based on the latest evidence and guidance; and Collaborate with an interdisciplinary team to integrate the latest guideline recommendations into individualized treatment plans tailored to patient and disease characteristics. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/ZSN860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Wanda Phipatanakul, MD, MS. In this activity, an expert in pediatric asthma discusses how to identify type 2 inflammation and tailor biologic therapy for pediatric patients with asthma. Upon completion of this activity, participants should be better able to: Identify the impact of type 2 inflammation on lung function in pediatric patients with asthma; Recognize best practices for incorporating biologics into the treatment of type 2 inflammatory pediatric asthma; and Outline the role of multidisciplinary teams in optimizing outcomes for pediatric patients with type 2 inflammatory asthma. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/860/102251349-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Charles L. Daley, MD, ATSF, FCCP; and David E. Griffith, MD, ATSF, FCCP. In this activity, experts in MAC lung disease discuss emerging first-line treatments and guideline-concordant, patient-centered strategies to individualize care for patients with newly diagnosed or refractory disease. Upon completion of this activity, participants should be better able to: Review the clinical profiles of emerging first-line treatments for Mycobacterium avium complex (MAC) lung disease in the context of standard of care regimens; Apply guideline-concordant strategies to develop individualized treatment plans for patients with newly diagnosed and refractory MAC lung disease; and Outline patient-centered strategies to enhance outcomes for patients with MAC lung disease receiving pharmacologic treatment.

Please visit answersincme.com/860/CME-26-207477-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Vallerie V. McLaughlin, MD; and Richard Channick, MD. In this activity, experts in pulmonary arterial hypertension (PAH) discuss strategies for personalized risk-based intensification of therapy for patients with PAH. Upon completion of this activity, participants should be better able to: Describe the rationale for risk-based treatment intensification strategies in patients with PAH. Identify clinical indicators warranting escalation of therapy in patients with intermediate- or high-risk PAH. Outline an evidence-based, personalized approach to integrating novel add-on therapies into treatment plans for patients with PAH. undefined In this activity, experts in pulmonary arterial hypertension (PAH) discuss strategies for personalized risk-based intensification of therapy for patients with PAH.